Search Results - small+molecules

131 Results

Sort By:

New Therapeutic Approach for the Treatment of Neuropathic Pain

Unmet NeedChronic pain affects around 50-million adults within the United States (see CDC). Currently the dominant treatment option for moderate to severe pain are opioids, which have a range of associated adverse effects as well as the potential for abuse. Despite the development of abuse-deterrent formulations, opioid dependence remains a major challenge....

Published: 3/13/2026 | Inventor(s): Takashi Tsukamoto, Barbara Slusher, Niyada Hin, Camilo Rojas, Xinzhong Dong, Yun Guan, Ilyas Berhane

Keywords(s): Agonists/Promoters, Chronic Pain, CNS and Neurological Disorders, Disease Indication, Small Molecules, Target, Therapeutic Matter, Therapeutic Substance, Therapeutics

Category(s): Clinical and Disease Specializations > Pain > Chronic Neuropathic Pain, Technology Classifications > Therapeutic Modalities > Targets, Technology Classifications > Therapeutic Modalities > Small Molecules

Targeting of Myeloid-Derived Suppressor Cells (MDSCs) for Cancer Treatment

Value Proposition· Addresses key resistance mechanism: targets MDSCs, a central driver of resistance to immune checkpoint inhibitors in metastatic and poorly immunogenic cancers· Synergistic combination strategy: Combines epigenetic modulators (HDAC and DNA methyltransferase inhibitors) with anti-PD-1 and anti-CTLA-4 antibodies to restore...

Published: 3/12/2026 | Inventor(s): KiBem Kim, Bert Vogelstein, Kenneth Kinzler, Shibin Zhou

Keywords(s): Antagonists/Inhibitors, Antibodies, Biologics, Cancers, Combination, Disease Indication, Non-novel, Predicted Novelty, Repurposed, Small Molecules, Targeted Therapy/Immunotherapy, Therapeutic Matter, Therapeutic Substance, Therapeutics, Therapy Type

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities > Immunotherapies, Technology Classifications > Therapeutic Modalities > Targets, Technology Classifications > Therapeutic Modalities > Antibodies, Technology Classifications > Therapeutic Modalities > Biologics, Technology Classifications > Therapeutic Modalities > Small Molecules, Technology Classifications > Therapeutic Modalities

Targeted chemo-immunotherapy delivery

Value PropositionEnhanced effect of immunotherapyTreatment for recurrent or metastatic diseaseImproved glioma treatment Unmet NeedImmunotherapy represents a new paradigm in cancer treatment. Molecules that effectively reverse the immune suppressing nature of cancer have the potential to enhance the body’s ability to work systemically combat cancer (Pardoll,...

Published: 3/12/2026 | Inventor(s): Dimitrios Mathios, Betty Tyler, Drew Pardoll, Henry Brem, Michael Lim

Keywords(s): Antagonists/Inhibitors, Cancers, Chemotherapy/Immunotherapy, Combination, Disease Indication, Non-novel, Predicted Novelty, Repurposed, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics, Therapy Type

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Immunology, Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities > Small Molecules, Technology Classifications > Therapeutic Modalities > Immunotherapies, Technology Classifications > Therapeutic Modalities

Anti-Fungal Drug Analogs to Treat Cancer by Preventing Angiogenesis and Hedgehog Pathway Activity

Value Proposition· Itraconazole is in clinical trials for cancer treatment as it is known to have antiangiogenic activity and anti-Hedgehog pathway activity, but its use has been limited by its potent inhibition of the drug metabolizing enzyme CYP3A4· The designed analog for itraconazole has greater antiangiogenic potency without CYP3A4 inhibition...

Published: 3/12/2026 | Inventor(s): Jun Liu, Wei Shi, Kalyan Kumar Pasunooti, Wukun Liu, Ruojing Li, Sarah Head, Yingjun Li

Keywords(s): Antagonists/Inhibitors, Cancers, Disease Indication, Eye Disorders, Macular Degeneration, Novel, Predicted Novelty, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities > Small Molecules, Technology Classifications > Therapeutic Modalities, Clinical and Disease Specializations > Ophthalmology > Macular Degeneration

Gut-specific serotonin transporter inhibitors for treatment of constipation

Value Proposition· Potent inhibition of serotonin transporter (SERT) in GI system· Luminally and or/peripherally-restricted SERT inhibitors· Result in enhanced action of serotonin in stimulation of GI motility· Spares the body of systemic and CNS effectsUnmet NeedConstipation-predominant IBS involves reduced gastrointestinal...

Published: 3/13/2026 | Inventor(s): Pankaj Pasricha, James Barrow, Qian Li, Pablo de Leon, Yifang Huang

Keywords(s): Antagonists/Inhibitors, Biomarker, Disease Indication, Gastrointestinal Disorders, Mechanism-of-action Biomarker, Non-novel, Predicted Novelty, Repurposed, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics

Category(s): Technology Classifications > Therapeutic Modalities > Targets, Clinical and Disease Specializations > Gastroenterology

Novel Oxazolidinones for Treatment of Bacterial Infections

Marketing Summary DraftNovel Oxazolidinones for Treatment of Bacterial InfectionsJHU Ref #: C14633Value Proposition· Belong to the same chemical family as Zyvox, marketed by Pfizer, but shows better efficacy· Positive activity demonstrated against M. tuberculosis· MIC values the same or better than the current antibiotics in the...

Published: 3/13/2026 | Inventor(s): Gyanu Lamichhane, J. Ippoliti

Keywords(s): Bacterial Infections, Disease Indication, Infectious Diseases, Novel, Predicted Novelty, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics

Category(s): Clinical and Disease Specializations, Technology Classifications > Therapeutic Modalities > Small Molecules, Clinical and Disease Specializations > Infectious Diseases, Technology Classifications > Therapeutic Modalities, Clinical and Disease Specializations > Infectious Diseases > Bacterial Infections

Small Molecule Neutral Sphingomyelinase 2 (nSMase2) Inhibitors

Unmet NeedNeutral sphingomyelinase 2 (nSMase2) is expressed in neurons and hydrolyzes sphingomyelin, producing the lipid ceramide, which functions in stress responses leading to apoptosis, cell growth arrest, and differentiation. Increased levels of ceramides have been associated with many neurological disorders, including Alzheimer’s disease, multiple...

Published: 3/13/2026 | Inventor(s): Takashi Tsukamoto, Niyada Hin, Ondrej Stepanek, Barbara Slusher, Camilo Rojas, Ajit Thomas

Keywords(s): Antagonists/Inhibitors, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics

Category(s): Technology Classifications > Therapeutic Modalities > Small Molecules

Inhibition of nSMase for the Treatment of Human Immunodeficiency Virus Infection

Unmet NeedHuman immunodeficiency virus (HIV) is a retrovirus that negatively impacts the immune system, leading to immunosuppression and increased susceptibility to secondary, opportunistic infections and some cancers. It is estimated that 36.7 million people worldwide are currently living with HIV. Presently, HIV has no cure and requires life-long...

Published: 3/13/2026 | Inventor(s): Norman Haughey, Barbara Slusher, Camilo Rojas

Keywords(s): Antagonists/Inhibitors, Disease Indication, HIV, Infectious Diseases, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics

Category(s): Technology Classifications > Therapeutic Modalities > Small Molecules, Clinical and Disease Specializations > Infectious Diseases > HIV

Discovery of Small Molecule Inhibitors of Neutral Sphingomyelinase 2 (nSMase2) for the Treatment of Neurodegenerative Diseases

Unmet NeedIn the brain, neutral sphingomyelinase 2 (nSMase2) is expressed in neurons and increased activity and expression of this enzyme has been associated with pro-inflammatory conditions observed in Alzheimer’s disease, multiple sclerosis and human immunodeficiency virus (HIV-1) patients. Inhibition of human nSMase2 may preserve neuronal function...

Published: 3/13/2026 | Inventor(s): Barbara Slusher, Camilo Rojas, Ajit Thomas, Radim Nencka, Michal Sala, Hubert Hrebabecky, Norman Haughey

Keywords(s): Alzheimer's Disease, Antagonists/Inhibitors, Assay, Clinical Diagnostics, CNS and Neurological Disorders, Disease Indication, In Vitro Diagnostics, Non-novel, Off-the-shelf, Predicted Novelty, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Neurology, Technology Classifications > Therapeutic Modalities > Small Molecules, Technology Classifications > Therapeutic Modalities, Clinical and Disease Specializations > Neurology > Alzheimer's Disease

Prodrug for Immunological and Oncological Therapy

Unmet NeedApproximately 1.24 million hematological cancer cases occur each year, accounting for approximately 6% of all cancer cases (Bristol Myers Squibb). Currently, standard treatment strategies include chemotherapy, radiation therapy, and stem cell transplants. However, there exist several major drawbacks for each method. Stem cell transplants can...

Published: 3/13/2026 | Inventor(s): Barbara Slusher, Rana Rais, Franco D'alessio, Pavel Majer, Marcela Krecmerova, Srinivasan Yegnasubramanian

Keywords(s): Blood Cancer, Cancers, Disease Indication, Inflammatory Disorders, Respiratory Infections, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutic Substance Synthesis Method, Therapeutics, Transplants

Category(s): Clinical and Disease Specializations > Oncology > Hematologic Malignancies, Clinical and Disease Specializations > Transplantation, Technology Classifications > Therapeutic Modalities > Small Molecules

1 2 3 4 5 6 7 8 9 10 ...